MRK
Merck & Co., Inc.NYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
16.37
PEG
2.46
P/B
5.72
P/S
4.60
EV/EBITDA
12.73
DCF Value
$158.58
FCF Yield
4.1%
Div Yield
2.7%
Margins & Returns
Gross Margin
81.5%
Operating Margin
41.2%
Net Margin
28.1%
ROE
36.2%
ROA
20.6%
ROIC
20.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $16.40B | $2.96B | $1.19 |
| FY 2025 | $65.01B | $18.25B | $7.28 |
| Q3 2025 | $17.28B | $5.79B | $2.32 |
| Q2 2025 | $15.81B | $4.43B | $1.76 |
Analyst Ratings
View AllTrading Activity
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
0.28
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.